

## Pharming to present at the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days

**Leiden, The Netherlands, March 30, 2023:** Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s Chief Executive Officer, Sijmen de Vries, and Chief Commercial Officer, Stephen Toor, will attend the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days, April 3 - 4, 2023 in New York.

Pharming’s CEO and CCO will take part in a fireside chat on April 3 at 15:20 ET /21:20 CEST.

A live webcast and replay of the fireside chat can be found in the “Upcoming Events” and “News” sections of Pharming’s website.

Pharming’s CEO and CCO will be available for one-to-one investor meetings during the conference.

For more information about the conference, or to schedule a one-to-one with Pharming’s management team, please contact your Guggenheim representative, or send an email to Pharming’s Investor Relations team to [investor@pharming.com](mailto:investor@pharming.com).

### About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit [www.pharming.com](http://www.pharming.com) or follow us on [LinkedIn](#).

### For further public information, contact:

*Pharming Group, Leiden, The Netherlands*

Michael Levitan, VP Investor Relations & Corporate Communications  
T: +1 (908) 705 1696

Heather Robertson, Investor Relations & Corporate Communications Manager  
T: +31 71 5247 400  
E: [investor@pharming.com](mailto:investor@pharming.com)

*FTI Consulting, London, UK*  
Victoria Foster Mitchell/Alex Shaw  
T: +44 203 727 1000

*FTI Consulting, USA*

Jim Polson

T: +1 (312) 553-6730

*LifeSpring Life Sciences Communication, Amsterdam, The Netherlands*

Leon Melens

T: +31 6 53 81 64 27

E: [pharming@lifespring.nl](mailto:pharming@lifespring.nl)